The Evidence Behind Nuvail
Cosmetic nail products do not need FDA approval before they go on the market. Nuvail® has a regulatory clearance and a small body of published literature.
Both are worth stating precisely, including where they stop. A page that overstated its own evidence would be doing the exact thing that makes this category hard to trust.
What has the FDA actually cleared Nuvail to do?
Nuvail holds 510(k) clearance number K120059, granted in May 2012. It is regulated as a Class I device under the liquid bandage classification. The cleared indication is managing signs and symptoms of nail dystrophy, specifically nail splitting and nail fragility, for intact or damaged nails.
The applicant of record is Chesson Laboratory Associates of Durham, North Carolina, with a decision date of May 17, 2012.
One thing worth knowing before you look it up. The FDA record lists the device name as LIQUID BANDAGE rather than Nuvail. To check it yourself, search the 510(k) database for K120059 and confirm the applicant is Chesson Laboratory Associates.
The clearance language reads, in full:
“Managing signs and symptoms of nail dystrophy, i.e., nail splitting and nail fragility, for intact or damaged nails.”
That indication is the boundary of what anyone should claim for this product, including us.
One correction worth making. The 2012 announcement from the company then marketing Nuvail described the milestone as an FDA approval. That is not what happened. Devices are cleared through the 510(k) pathway by demonstrating substantial equivalence to an existing legally marketed device. New drugs go through a separate FDA approval process. The distinction is not a technicality, and a brand that leans on its regulatory status should get its own vocabulary right.
What do the published studies show?
The published studies cited here are two papers: a laboratory study of poly-ureaurethane 16% and a clinical evaluation in 63 people with fungal nail infection. Together they describe how the film behaves in the laboratory and report changes in nail appearance over six months in one uncontrolled study. Neither is a controlled study showing that Nuvail treats any condition.
The laboratory study (2016)
Adigun and colleagues published in vitro release testing in the Journal of Drugs in Dermatology. The study asked whether two topical antifungals, efinaconazole 10% and tavaborole 5%, could pass through a poly-ureaurethane film applied to a membrane. Both did.
That result matters for a specific question, which is whether the film would block a prescribed treatment. In this laboratory test the film did not block either drug, so it is not expected to interfere with a prescribed topical antifungal. Ask your prescriber. The study involved no organisms and no patients, so it says nothing about treating infection.
Disclosure worth stating plainly. Two authors were employees of the company then marketing Nuvail, two others served as its consultants, and the testing laboratory worked under contract to that company. Industry-sponsored research is common in this field. Readers should still know who paid for it.
The clinical evaluation (63 enrolled, 53 completed)
This is the only clinical study among the published research cited here, and its design matters as much as its results.
Sixty-three adults with onychomycosis of a great toenail, primarily culture-confirmed, were enrolled. Fifty-three completed the six-month study period, applying the product on a regimen set by the study protocol.
What it reported at six months: improvement in clinical nail parameters in 60% of subjects. Three minor adverse events were judged related to the product, and none were serious.
Two limitations that govern how far this goes.
It was single-arm and self-controlled, with no comparison group. Without one, improvement cannot be separated from the natural course or from six months of consistent nail care.
The population was people with confirmed fungal infection, not people with the splitting and fragility the product is cleared to manage. So it does not directly measure the cleared indication.
What has not been studied?
No large randomized controlled trial of Nuvail exists. It is not cleared to treat infection or an underlying medical condition, and none of the studies cited here show that it works faster than the nail grows. Anyone claiming otherwise, about this product or any other in the category, is ahead of the data.
Being specific about the gaps:
- Not an antifungal. Nuvail is not an antifungal and is not cleared to treat or prevent fungal infection. See when nail fungus turns out not to be fungus.
- Not a disease treatment. It is not cleared to treat psoriasis, thyroid conditions, diabetes-related nail changes, or chemotherapy nail changes. It was cleared for splitting and fragility.
- No head-to-head trials. No published study compares it directly against nail hardeners, biotin, or other over-the-counter products.
- No large randomized controlled trial. The clinical evaluation was a single-arm study that enrolled 63 people, not a randomized controlled trial.
A 2005 review estimated that brittle nails affect about 20% of the population, with women affected about twice as often as men. A condition that common deserves better evidence than this category has generated.
How should you read evidence in this category?
Ask three questions. Was it tested in people or only in a laboratory. How many people, and for how long. And does the claim being made actually match what was measured.
Cosmetic nail products are not required to go through FDA premarket review. That is worth knowing before comparing a price tag against a claim on a box.
Ask whether a product has a regulatory status such as FDA clearance, then read what that clearance actually covers, rather than what the marketing says about it.
For a plain explanation of what the film does, see how Nuvail works on damaged nails.
Where to get Nuvail
Nuvail is sold directly at nuvail.com in a 15 mL bottle with the applicator included. Shipping is free within the United States, and orders are processed within 24 to 48 hours.
The product was previously only available by prescription, and the formulation sold today is the same one dispensed then.
Nuvail is indicated for managing signs and symptoms of nail dystrophy, i.e., nail splitting and nail fragility, for intact or damaged nails. This content is for educational purposes and is not medical advice. Talk to your dermatologist or healthcare provider about persistent nail changes.
Sources
- U.S. Food and Drug Administration, 510(k) Premarket Notification K120059
- Adigun CG, et al. Efinaconazole 10% and tavaborole 5% penetrate across poly-ureaurethane 16%. J Drugs Dermatol. 2016;15(9):1116-1120
- Nasir A, et al. Clinical evaluation of safety and efficacy of a new topical treatment for onychomycosis. J Drugs Dermatol. 2011;10(10):1186-1191
- van de Kerkhof PCM, et al. Brittle nail syndrome: a pathogenesis-based approach with a proposed grading system. J Am Acad Dermatol. 2005;53(4):644-651
- Innocutis press release announcing the 2012 FDA "approval" (PR Newswire, Sept. 18, 2012)
- U.S. Food and Drug Administration, Premarket notification 510(k)
- U.S. Food and Drug Administration, FDA authority over cosmetics
- U.S. Food and Drug Administration, Is it really FDA approved?